Last reviewed · How we verify

NCT07454499

Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)

Not yet recruiting NA Last updated 6 March 2026
What this trial tests

NA trial testing Digital Endocrine therapy Symptom Monitoring and Education Intervention in Cancer in 60 participants. Not yet recruiting.

Timeline
1 April 2026
Primary endpoint
30 November 2027
31 December 2027

Quick facts

Lead sponsorAbramson Cancer Center at Penn Medicine
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment60
Start date1 April 2026
Primary completion30 November 2027
Estimated completion31 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, female only, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to learn more about ways to help patients understand and manage side-effects from hormone therapy. The investigators will use the information from this study to design future studies to better understand how our well our tools work to help patients monitor and manage symptoms from hormone therapy and to stay on their hormone therapy for the recommended period of time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Abramson Cancer Center at Penn Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07454499.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing